Table 2.

Immunologic characterization of Serum Pools

Primary Vaccine	Boost	Days post-final vaccine	Anti-S Ab*	Anti-Nucleocapsid Ab	RBD blocking IC90	Neutralization EC50 (IU/ml) EC50 (IU/ml) EC50 (IU/ml)
BNT162b2		69	1,312	Neg	60	5.01	4.47	5.01
mRNA-1273		102	1,447	Neg	64	5.01	3.98	5.01
Ad26.COV2.S		83	1,936	Neg	118	5.01	6.31	3.16
NVX-CoV2373		152†	605	Neg	46	2.00	2.82	1.41
BNT162b2	BNT152b2	63	10,062	Neg	6.6 × 104	8.91	7.94	10.00
mRNA-1273	mRNA-1273	89	4,959	Neg	1.1 × 106	4.47	5.01	3.55
NVX-CoV2373	NVX-CoV2373	46	22,572	Neg	2.5 × 106	6.31	3.55	7.94
BNT162b2	mRNA-1273	55	7,140	Neg	6.6 × 104	10.00	12.59	8.91
NVX-CoV2373	BNT162.b2	43	45,720	Neg	2.2 × 106	4.47	3.16	4.47
Ad26.COV2. S	BNT162.b 2	178	2,014	Neg	4.3 × 104	3.98	3.98	5.01
Ad26.COV2. S	mRNA-1273	126	9,342	Neg	1.4 × 106	3.98	6.31	3.16

Anti-S = anti-spike protein binding antibody,

^*W.H.O. IU/mL estimated (see text). ELISA,

^†NVX-CoV2373 in blinded clinical trial, result is estimated (see text). RBD = reciprocal of the serum dilution required to reduce receptor binding to ACE-2 by 90%. Data represent the results of experiments performed in triplicate